Corrigendum to “A Prominin-1–Rich Pediatric Glioblastoma: Biologic Behavior Is Determined by Oxygen Tension-Modulated CD133 Expression But Not Accompanied by Underlying Molecular Profiles” (Translational Oncology (2012) 5(3) (141–IN1), (S1936523312800027) (10.1593/tlo.11337));A Prominin-1-rich pediatric glioblastoma: Biologic behavior is determined by oxygen Tension-Modulated CD133 Expression but Not Accompanied by Underlying Molecular Profiles1,2

Translational Oncology

Volumn 5, Issue 3, 2012, Pages 141-154

  Donovan, Laura K ^a   Potter, Nicola E ^b   Warr, Tracy ^c   Pilkington, Geoffrey J ^a  

^a UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^c UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; GENOMIC DNA; GLYCOPROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; TUMOR MARKER;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER CELL IN699; CANCER STEM CELL; CD133+VE T LYMPHOCYTE; CD133-VE T LYMPHOCYTE; CELL ADHESION; CELL CYCLE; CELL LINE; CELL MIGRATION; CELL POPULATION; CELL PROLIFERATION; CELL SELECTION; CELL VOLUME; CHILDHOOD CANCER; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; DNA EXTRACTION; FLOW CYTOMETRY; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOCYTOCHEMISTRY; MOLECULAR BIOLOGY; NEURAL STEM CELL; OXYGEN TENSION; PEDIATRIC GLIOBLASTOMA; T LYMPHOCYTE;

EID: 84862001244     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1016/j.tranon.2017.09.010     Document Type: Erratum

References (71)

1. Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, Bronner-Fraser M, and Kornblum HI (2003). Cancerous stem cells can arise from paediatric brain tumours. Proc Natl Acad Sci USA 100(25), 15178-15183.
2. Brustle O and McKay RD (1995). The neuroepithelial stem cell concept: implications for neuro-oncology. J Neurooncol 24(1), 57-59.
3. Valtz NL, Hayes TE, Norregaard T, Liu SM, and McKay RD (1991). An embryonic origin for medulloblastoma. New Biol 3(4), 364-371.
4. Alvarez-Buylla A and Garcia-Verdugo JM (2002). Neurogenesis in adult subventricular zone. J Neurosci 22(3), 629-634.
5. Wechsler-Reya R and Scott MP (2001). The development biology of brain tumours. Annu Rev Neurosci 24, 385-428.
6. Corbeil D, Röper K, Hellwig A, Tavian M, Miraglia S, Watt SM, Simmons PJ, Peault B, Buck DW, and Huttner WB (2000). The human AC133 haematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem 275(8), 5512-5520.
7. Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N, Lichter P, Unterberg A, Radlwimmer B, and Herold-Mende CC (2008). Stem cell marker CD133 affects clinical outcome in gliomas patients. Clin Cancer Res 14(1), 123-129.
8. + cancer stem cells in glioblastoma. Mol Cancer 5, 67.
9. + sector is enlarged by hypoxia. Int J Radiat Oncol Biol Phys 67(1), 1-5.
10. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, and Rich JN (2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444(7120), 756-760.
11. Carmeliet P and Jain RK (2000). Angiogenesis in cancer and other diseases. Nature 407(6801), 249-257.
12. Kohshi K, Kinoshita Y, Imada H, Kunugita N, Abe H, Terashima H, and Tokui S (1999). Effects of radiotherapy after hyperbaric oxygenation on malignant glioma. Br J Cancer 80(1-2), 236-241.
13. Keith B and Simon MC (2007). Hypoxia-inducible factors, stem cells and cancer. Cell 129(3), 465-472.
14. Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, and Van Meir EG (2005). Hypoxia and the hypoxia-inducible factor pathway in glioma growth and angiogenesis. Neuro Oncol 7(2), 134-153.
15. Wang J, Sakariassen PØ, Tsinkalovsky O, Immervoll H, Bøe SO, Svendsen A, Prestegarden L, Røsland G, Thorsen F, Stuhr L, et al. (2008). CD133 negative glioma cells form tumours in nude rats and give rise to CD133 positive cells. Int J Cancer 122(4), 761-768.
16. -glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 67(9), 4010-4015.
17. Joo KM, Kim SY, Jin X, Song SY, Kong DS, Lee JI, Jeon JW, Kim MH, Kang BG, Jung Y, et al. (2008). Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab Invest 88(8), 808-815.
18. Ward SJ, Karakoula K, Phipps KP, Harkness W, Hayward R, Thompson D, Jacques TS, Harding B, Darling JL, Thomas DG, et al. (2010). Cytogenetic analysis of paediatric astrocytoma using comparative genomic hybridisation and fluorescence in-situ hybridisation. J Neurooncol 98, 305-318.
19. Csete M (2005). Oxygen in the cultivation of stem cells. Ann N Y Acad Sci 1049, 1-8.
20. Sullivan M, Galea P, and Latif S (2006). What is the appropriate oxygen tension for in vitro culture? Mol Hum Reprod 12(11), 653.
21. Cheng JX, Liu BL, and Zhang X (2009). How powerful is CD133 as a cancer stem cell marker in brain tumours? Cancer Treat Rev 35(5), 403-408.
22. Pilkington GJ (2005). Cancer stem cells in the mammalian central nervous system. Cell Prolif 38(6), 423-433.
23. Vescovi AL, Galli R, and Reynolds BA (2006). Brain tumour stem cells. Nat Rev Cancer 6(6), 425-436.
24. Sakakibara S, Imai T, Hamaguchi K, Okabe M, Aruga J, Nakajima K, Yasutomi D, Nagata T, Kurihara Y, Uesugi S, et al. (1996). Mouse-Musashi-1, a neural RNA-binding protein highly enriched in the mammalian CNS stem cell. Dev Biol 176(2), 230-242.
25. Uchida K, Mukai M, Okano H, and Kawase T (2004). Possible oncogenicity of subventricular zone neural stem cells: case report. Neurosurgery 55(4), 977-978.
26. + cells correlates with malignancy of gliomas. Mol Cell Neurosci 43(1), 51-59.
27. Okano H, Imai T, and Okabe M (2002). Musashi: a translational regulator of cell fate. J Cell Sci 115(7), 1355-1359.
28. Kanemura Y, Mori K, Sakakibara S, Fujikawa H, Hayashi H, Nakano A, Matsumoto T, Tamura K, Imai T, Ohnishi T, et al. (2001). Musashi1, an evolutionary conserved neural RNA-binding protein, is a versatile marker of human glioma cells in determining their cellular origin, malignancy, and proliferative activity. Differentiation 68(2-3), 141-152.
29. Zhang M, Song T, Yang L, Chen R, Wu L, Yang Z, and Fang J (2008). Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients. J Exp Clin Cancer Res 27, 85.
30. Lendahl U, Zimmerman LB, and McKay RD (1990). CNS stem cells express a new class of intermediate filament protein. Cell 60(4), 585-595.
31. Thomas SK, Messam CA, Spengler BA, Biedler JL, and Ross RA (2004). Nestin is a potential mediator of malignancy in human neuroblastoma cells. J Biol Chem 279(27), 27994-27999.
32. Ligon KL, Huillard E, Mehta S, Kesari S, Liu H, Alberta JA, Bachoo RM, Kane M, Louis DN, Depinho RA, et al. (2007). Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron 53(4), 503-517.
33. Azzarelli B, Miravalle L, and Vidal R (2004). Immunolocalisation of the oligodendrocyte transcription factor 1 (Olig 1) in brain tumours. J Neuropathol Exp Neurol 63(2), 170-179.
34. Bouvier C, Bartoli C, Aquirre-Cruz L, Virad I, Colin C, Fernandez C, Gouvernet J, and Figarella-Branger D (2003). Shared oligodendrocyte lineage gene expression in gliomas and oligodendrocyte progenitor cells. J Neurosurg 99(2), 344-350.
35. Lgon KL, Alberta JA, Kho AT, Weiss J, Kwann MR, Nutt CL, Louis DN, Stiles CD, and Rowitch DH (2004). The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas. JNeuropathol Exp Neurol 63(5), 499-509.
36. Marie Y, Sanson M, Mokhtari K, Leuraud P, Kujas M, Delattre JY, Poirier J, Zalc B, and Hoang-Xuan K (2001). OLIG2 as a specific marker of oligodendroglial tumour cells. Lancet 358(9278), 298-300.
37. Kippin TE, Martens DJ, and Van der Kooy D (2005). p21 loss compromises the relative quiescence of forebrain stem cell proliferation leading to exhaustion of their proliferation capacity. Genes Dev 19(6), 756-767.
38. Gangemi RM, Grifffero F, Marubbi D, Perera M, Capra MC, Malatesta P, Ravetti GL, Zona GL, Daga A, and Corte G (2009). Sox2 silencing in glioblastoma tumour-initiating cells causes stop of proliferation and loss of tumourigenicity. Stem Cells 27(1), 40-48.
39. Rodriguez-Pinilla SM, Sarrio D, Moreno-Bueno G, Rodriguez-Gil Y, Martinez MA, Hernandez L, Hardisson D, Reis-Filho JS, and Palacios J (2007). Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. Mod Pathol 20(4), 474-481.
40. Schmitz M, Temme A, Senner V, Ebner R, Schwind S, Stevanovic S, Wehner R, Schackert G, Schackert HK, Fussel M, et al. (2007). Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy. Br J Cancer 96(8), 1293-1301.
41. Gu G, Yuan J, Wills M, and Kasper S (2007). Prostate cancer cells with stem cell characteristics reconstitute the original human tumour in vivo. Cancer Res 67(10), 4807-4815.
42. Phi JH, Park SH, Paek SH, Kim SK, Lee YJ, Park CK, Cho BK, Lee DH, and Wang KC (2007). Expression of Sox2 in mature and immature teratomas of central nervous system. Mod Pathol 20(7), 742-748.
43. Spisek R, Kukreja A, Chen LC, Matthews P, Mazumder A, Vesole D, Jagannath S, Zebroski HA, Simpson AJ, Ritter G, et al. (2007). Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J Exp Med 204(4), 831-840.
44. Otsubo T, Akiyama Y, Yanagihara K, and Yuasa Y (2008). SOX2 is frequently downregulated in gastric cancers and inhibits cell growth through cell-cycle arrest and apoptosis. Br J Cancer 98(4), 831-840.
45. + glioblastoma stem cells derived from treatment-refractory recurrent brain tumours. J Neurooncol 94(1), 1-19.
46. Son MJ, Woolard K, Nam DH, Lee J, and Fine HA (2009). SSEA-1 is an enrichment marker for tumour-initiating cells in human glioblastoma. Cell Stem Cell 4(5), 440-452.
47. Martin K, Akinwunmi J, Rooprai HK, Kennedy AJ, Linke A, Ognejenovic N, and Pilkington GJ (1995). Nonexpression of CD15 by neoplastic glia: a barrier to metastasis? Anticancer Res 15(4), 1159-1166.
48. Rebetz J, Tian D, Persson A, Widegren B, Salford LG, Englund E, Gisselsson D, and Fan X (2008). Glial progenitor-like phenotype in low-grade glioma and enhanced CD133-expression and neuronal lineage differentiation potential in high-grade glioma. PLoS One 3(4), e1936.
49. Sanai N, Alvarez-Buylla A, and Berger MS (2005). Neural stem cells and the origin of gliomas. N Engl J Med 353(8), 811-822.
50. Chekenya M and Pilkington GJ (2002). NG2 precursor cells in neoplasia: functional, histogenesis and therapeutic implications for malignant brain tumours. J Neurocytol 31(6-7), 507-521.
51. Buick RN, Minden MD, and McCulloch EA (1979). Self-renewal in culture of proliferative blast progenitor cells in acute myeloblastic leukaemia. Blood 54(1), 95-104.
52. Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, and Fuller GN (2000). Combined activation of Ras and Akt in neural progenitors induces glioblastoma formations in mice. Nat Genet 25(1), 55-57.
53. Gustafsson MV, Zheng X, Pereira T, Gradin K, Jin S, Lundkvist J, Ruas JL, Poellinger L, Lendahl U, and Bondesson M (2005). Hypoxia requires notch signalling to maintain the undifferentiated cell state. Dev Cell 9(5), 617-628.
54. Gordan JD, Bertout JA, Hu CJ, Diehl JA, and Simon MC (2007). HIF2-α promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 11(4), 335-347.
55. Patel SA and Simon MC (2008). Biology of hypoxia-inducible factor-2α in development and disease. Cell Death Differ 15(4), 628-634.
56. LashGE, Fitzpatrick TE, and Graham CH (2001). Effect of hypoxia on cellular adhesion to vitronectin and fibronectin. Biochem Biophys Res Commun 287(3), 622-629.
57. Pilkington GJ (1994). Tumour cell migration in the central nervous system. Brain Pathol 4(2), 157-166.
58. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, and Krek W (2003). Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 425(6955), 307-311.
59. Hasan NM, Adams GE, Joiner MC, Marshall JF, and Hart IR (1998). Hypoxia facilitates tumour cell detachment by reducing expression of surface adhesion molecules and adhesion to extracellular matrices without loss of viability. Br J Cancer 77(11), 1799-1805.
60. Hall PE, Lathita JD, Miller NG, Caldwell MA, and Ffrench-Constant C (2006). Integrins are markers of human neural stem cells. Stem Cells 24(9), 2078-2084.
61. Kemper K, Sprick MR, de BreeM, Scope A, Vermeulen L, Hoek M, Zeilstra J, Pals ST, Mehmet H, Stassi G, et al. (2010). The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res 70(2), 719-729.
62. Campos B, Zeng L, Daotrong PH, Eckstein V, Unterberg A, Mairbäurl H, and Herold-Mende C (2011). Expression and regulation of AC133 and CD133 in glioblastoma. Glia 59(12), 1974-1986.
63. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, Olweus J, Kearney J, and Buck DW (1997). AC133, a novel marker for human haematopoietic stem and progenitor cells. Blood 90(12), 5002-5012.
64. Ono M and Hakomori S (2004). Glycosylation defingin cancer cell motility and invasiveness. Glycoconj J 20(1), 71-78.
65. Hakomori S (1996). Tumour malignancy defined by aberrant glycosylation and sphingo(glycol)lipid metabolism. Cancer Res 56(23), 5309-5318.
66. Birks SM, Danquah JO, King L, Vlasak R, Gorecki DC, and Pilkington GJ (2011). Targeting the GD3 acetylation pathway selectively induces apoptosis in glioblastoma. Neuro-oncology 13(9), 950-960.
67. Taïeb N, Maresca M, Guo XJ, Garmy N, Fantini J, and Yahi N (2009). The first extracellular domain of the tumour stem cell marker CD133 contains an antigenic ganglioside-binding motif. Cancer Lett 278(2), 164-173.
68. Carroll VA and Ashcroft M (2006). Role of hypoxia-inducible factor (HIF)-1α versus HIF-2α in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res 66(12), 6264-6270.
69. -glioblastoma-derived cancer stem cell lines suggest different cells of origin. Cancer Res 70(5), 2030-2040.
70. Gaiser T, Camps J, Meinhardt S, Wangsa D, Nguyen QT, Varma S, Dittfield C, Kunz-Schughart LA, Kemmerling R, Becker MR, et al. (2011). Genome and transcriptome profiles of CD133-positive colorectal cancer cells. Am J Pathol 178, 1478-1488.
71. Wan F, Herold-Mende C, Campos B, Centner FS, Dictus C, Becker N, Devens F, Mogler C, Felberg J, Grabe N, et al. (2011). Association of stem cell-related markers and survival in astrocytic gliomas. Biomarkers 16(2), 136-143.